Correlation between MicroRNA-155 Expression and Viral Load in Severe COVID-19 Patients

  • Bareq N Al-Nuaimi Departement of Biology, College of Science, University of Baghdad, Baghdad, Iraq. Department of Microbiology, College of Medicine, Al-Iraqia University, Baghdad, Iraq.
  • Raghad H Al-Azzawi Departement of Biology, College of Science, University of Baghdad, Baghdad, Iraq.
Keywords: Microrna-155, Mir-155, Covid-19, Viral Load, SARS-CoV-2

Abstract

Background: The SARS-CoV-2 virus causes COVID-19, a respiratory syndrome. It causes inflammation and damages several organs in the body. miRNAs play a role in regulating the infection resulting from SARS-CoV-2. MicroRNA-155, a kind of microRNA linked to viral defences, can affect the immune responses during COVID-19.
Objectives: Examination of the involvement of microRNA-155 in the development and severity of COVID-19, as well as finding the correlation between microRNA-155 and viral load (copies/mL) in severe cases of the disease.
Materials and Method: A case-control research study was performed between October 2022 and June 2023. It included a cohort of 120 hospitalised individuals with severe cases of COVID-19, together with 115 individuals with mild cases of COVID-19 and apparently healthy individuals. A real-time PCR procedure was applied to determine microRNA-155 expression in the studied groups and the viral load (copies/mL) in severe cases of the disease.
Results: MicroRNA-155 was expressed in severe cases threefold more than its expression in mild cases of COVID-19 and healthy individuals. Also, a strong association was demonstrated between microRNA-155 and viral load (copies/mL) in severe COVID-19.
Conclusion: MicroRNA-155 could be used as a biomarker for severe COVID-19 conditions and could have a role in disease severity and infectious particles of the virus. Since it is positively correlated with viral load (copies/mL) in severe cases of the disease.

How to cite this article:
Al-Nuaimi B N, Al-Azzawi R H. Correlation
between MicroRNA-155 Expression and Viral
Load in Severe COVID-19 Patients. J Commun
Dis. 2024;56(4):1-7.

DOI: https://doi.org/10.24321/0019.5138.202463

References

Dadras O, Alinaghi SA, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, Pashaei Z, Mirzapour P, Fakhfouri

Published
2025-02-04